• Gilead Sciences reached an agreement on October 22, 2026, to settle Texas False Claims Act litigation involving its patient support programs.
• The settlement requires a payment, dismissal with prejudice and release of all claims by Texas and Health Choice Advocates.
• The company denies the allegations, citing the cost and distraction of prolonged litigation as its reasons for settling.
• Patient support programs will remain available in Texas and across the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.